Phenotypic and Functional Characterization of CCR9+ T Lymphocytes in Small Intestinal Crohn’s Disease (CD)

Daocheng Zhu, Armine Avanesyan, and Konstantinos A. Papadakis

Inflammatory Bowel Disease Center
Cedars-Sinai Medical Center
Los Angeles, CA
Abstract

The chemokine receptor CCR9 and its ligand thymus-expressed chemokine (TECK)/CCL25 play a critical role in the selective homing of T lymphocytes to the small intestine (SI). CCR9+ T cells represent a small subset of PBL with mucosal T cell characteristics, including an activated phenotype, responsiveness to CD2 pathway, and a Th1/Tr1 cytokine profile. In addition the frequency of CCR9+ T lymphocytes is increased in the circulation of patients with SI CD and celiac disease implicating this T cell subset in the pathogenesis of SI immune-mediated diseases. In this report, we have characterized the phenotype and cytokine profile of CCR9+ T lymphocytes in SI CD. Compared to normal donors, patients with SI CD show an increased percentage of CCR9+ T cells in the circulation and draining mesenteric lymph nodes (MLN) with an activated phenotype (expression of OX-40, CD40L and HLA-DR). Interestingly, we found no difference in the expression of these markers between inflamed and normal SI lamina propria lymphocytes (LPL). Both CCR9+ T cells isolated from normal and inflamed intestine exhibit a Th1 cytokine profile as assessed by intracellular cytokine staining. Interestingly, CCR9+ T cells isolated from PB and SI respond to cytokine stimulation with IL-12 plus IL-18 with enhanced IFN-γ production. The addition of TL1A (a newly-discovered TNF-like cytokine) augmented IFN-γ production by cytokine-stimulated CCR9+ LP T cells by 37 to 105-fold. Based on these data we conclude that CCR9+ T cells in both MLN and PB show an activated phenotype in SI CD. In addition, they exhibit a predominant Th1 cytokine profile in response to polyclonal or cytokine stimulation. Since CCR9+ T cells appear to have a pro-inflammatory cytokine profile, the use of selective CCR9 antagonists could represent a novel treatment for SI CD.
Introduction

- TECK/CCL25 and CCR9 are involved in the selective trafficking of T lymphocytes to the SI.
- The frequency of CCR9+ T cells are increased in the circulation of patients with SI immune-mediated diseases, including CD.
- The small subset of CCR9+ T cells in the PB has mucosal T cell characteristics with an activated phenotype, responsiveness to CD2 stimulation and a Th1/Tr1 cytokine profile.
Aim

Determine the phenotype and cytokine profile of CCR9+ T cells in mucosal lymphoid tissues in patients with SI CD.
Methods

- Purified CCR9+ T cells were stimulated with IL-12 (2 ng/ml), IL-18 (50 ng/ml) with or without TL1A
- IFN-γ production was analyzed by ELISA and intracellular staining
- The phenotype of CCR9+ T cells was analyzed by FACS
RESULTS
Phenotypic characteristics of CCR9+ T cells from normal and inflamed SI Lymphoid tissues and PB

Phenotype of SI CCR9+ T Lymphocytes

- CD25
- CD69
- OX40
- CTLA4
- CD40L
- HLA-DR

Normal SI
Inflamed SI
Phenotypic characteristics of CCR9+ T cells from normal and inflamed SI Lymphoid tissues and PB

Phenotype of MLN CCR9+ T Lymphocytes

- CD25
- CD69
- OX40
- CTLA4
- CD40L
- HLA-DR

% of marker-positive cells
Phenotypic characteristics of CCR9+ T cells from normal and inflamed SI Lymphoid tissues and PB

Phenotype of PB CCR9+ T Lymphocytes

% of marker-positive cells

<table>
<thead>
<tr>
<th>Protein</th>
<th>Normal Donors</th>
<th>SI CD</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OX40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTLA4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD40L</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CXCR3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCR5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-DR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Phenotypic characteristics of CCR9+ T cells from normal and inflamed SI Lymphoid tissues and PB

LPL or MLN Lymphocytes were isolated from normal and inflamed SI and stained for CD3-FITC, CCR9 Ab followed by a secondary anti-mouse-IgG2b-TC Ab and PE-conjugated antibodies for the indicated activation markers and co-stimulatory molecules and analyzed by FACS. The data represent the mean ± SEM from 5 different donors. PBL (lower panel) from normal donors and patients with SI CD were stained in a similar way and analyzed by FACS. The bars represent the mean ± SEM from 10 different normal donors and 5 CD patients.

**Conclusions:**
CCR9+ T cells in MLN and PB have an activated phenotype in SI CD
CCR9+ T lymphocytes in normal and inflamed SI have a Th1 cytokine profile
CCR9+ T lymphocytes in normal and inflamed SI have a Th1 cytokine profile

SI LPL were isolated from normal and inflamed mucosa, activated with PMA (50 ng/ml) and ionomycin (1 μg/ml) for 4 hours and stained with CD3-FITC and CCR9-TC. The cells were fixed and permeabilized with saponin and stained with an IFN-γ-PE or isotype control Ab and analyzed by FACS. The frequency of CCR9+IFN-γ+ T cells ranged from 53% to 85% in normal donors (n=3) and 44% to 64% in CD patients (n=5).
TL1A augments IFN-γ production by IL-12 and IL-18-stimulated CCR9+ T cells

**A** and **B**. Sorted CCR9+ T cells from PB were stimulated with IL-12/IL-18 ± TL1A. Culture supernatants were collected 72 hrs later and analyzed for IFN-γ content by ELISA.
TL1A augments IFN-γ production by IL-12 and IL-18-stimulated CCR9+ T cells

C. Intracellular IFN-γ staining in cytokine-stimulated CCR9+ and CCR9- T cells.
TL1A augments IFN-γ production by IL-12 and IL-18-stimulated CCR9+ T cells

D. Sorted CCR9+ T cells were incubated with IL-12 plus IL-18 with anti-TL1A or isotype control Ab. Culture supernatants were collected 72 hrs later and analyzed for IFN-γ content by ELISA.
TL1A augments IL-12/IL-18-induced IFN-γ production by both PB and mucosal CCR9+ T cells

Table 1. **TL1A enhances IFN-γ production by cytokine-stimulated PB CCR9+CD4+ T cells**

<table>
<thead>
<tr>
<th>PB CCR9+CD4+</th>
<th>IL-12/IL-18-induced IFN-γ (ng/ml)</th>
<th>IL-12/IL-18 plus TL1A induced IFN-γ (ng/ml)</th>
<th>Fold enhancement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor 1</td>
<td>1.7</td>
<td>21.7</td>
<td>13</td>
</tr>
<tr>
<td>Donor 2</td>
<td>23</td>
<td>82.2</td>
<td>3.6</td>
</tr>
<tr>
<td>Donor 3</td>
<td>23.7</td>
<td>115</td>
<td>4.8</td>
</tr>
<tr>
<td>Donor 4</td>
<td>0.195</td>
<td>10.7</td>
<td>55</td>
</tr>
</tbody>
</table>

FACS-sorted PB CCR9+CD4+ T cells were stimulated with IL-12 (2 ng/ml) plus IL-18 (50 ng/ml) with or without TL1A (100 ng/ml) for 72 hrs. Culture supernatants were analyzed for IFN-γ content by ELISA.
TL1A augments IL-12/IL-18-induced IFN-γ production by both PB and mucosal CCR9+ T cells

Table 2. TL1A enhances IFN-γ production by cytokine-stimulated SI CCR9+CD4+ T cells.

<table>
<thead>
<tr>
<th>SI CCR9⁺CD4⁺</th>
<th>IL-12/IL-18-induced IFN-γ (ng/ml)</th>
<th>IL-12/IL-18 plus TL1A-induced IFN-γ (ng/ml)</th>
<th>Fold enhancement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donor 1</td>
<td>0.347</td>
<td>39.3</td>
<td>105</td>
</tr>
<tr>
<td>Donor 2</td>
<td>2</td>
<td>93.74</td>
<td>47</td>
</tr>
<tr>
<td>Donor 3</td>
<td>2.2</td>
<td>82</td>
<td>37</td>
</tr>
</tbody>
</table>

FACS-sorted SI CCR9⁺CD4⁺ T cells were stimulated with IL-12 (2 ng/ml) plus IL-18 (50 ng/ml) with or without TL1A (100 ng/ml) for 72 hrs. Culture supernatants were analyzed for IFN-γ content by ELISA.
TL1A augments IL-12/IL-18-induced IFN-γ production by both PB and mucosal CCR9+ T cells

Conclusions:

- TL1A augments IL-12/IL-18-induced IFN-γ production in PB and SI CCR9+ T cells
- Endogenous TL1A/DR3 interactions contribute to cytokine-induced IFN-γ production in CCR9+ T cells
Summary

- CCR9+ T lymphocytes have an activated phenotype in PB and MLN in SI CD
- CCR9+ T lymphocytes exhibit Th-1 cytokine profile in both normal and inflamed SI
- CCR9+ PB and SI T lymphocytes respond to IL-12 plus IL-18 with IFN-γ production which is markedly augmented by TL1A
Conclusion

- CCR9+ T lymphocytes have a pro-inflammatory cytokine profile
- CCR9 antagonists could represent a novel and selective treatment for SI CD